Literature DB >> 21740955

Mechanism of stereoselective interaction between butyrylcholinesterase and ethopropazine enantiomers.

Goran Sinko1, Zrinka Kovarik, Elsa Reiner, Vera Simeon-Rudolf, Jure Stojan.   

Abstract

Stereoselectivity of reversible inhibition of butyrylcholinesterase (BChE; EC 3.1.1.8) by optically pure ethopropazine [10-(2-diethylaminopropyl)phenothiazine hydrochloride] enantiomers and racemate was studied with acetylthiocholine (0.002-250 mM) as substrate. Molecular modelling resulted in the reaction between BChE and ethopropazine starting with the binding of ethopropazine to the enzyme peripheral anionic site. In the next step ethopropazine 'slides down' the enzyme gorge, resulting in interaction of the three rings of ethopropazine through π-π interactions with W82 in BChE. Inhibition mechanism was interpreted according to three kinetic models: A, B and C. The models differ in the type and number of enzyme-substrate, enzyme-inhibitor and enzyme-substrate-inhibitor complexes, i.e., presence of the Michaelis complex and/or acetylated BChE. Although, all three models reproduced well the BChE activity in absence of ethopropazine, model A was poor in describing inhibition with ethopropazine, while models B and C were better, especially for substrate concentrations above 0.2 mM. However model C was singled out because it approaches fulfilment of the one step-one event criteria, and confirms the inhibition mechanism derived from molecular modelling. Model C resulted in dissociation constants for the complex between BChE and ethopropazine: 61, 140 and 88 nM for R-enantiomer, S-enantiomer and racemate, respectively. The respective dissociation constants for the complexes between acetylated BChE and ethopropazine were 268, 730 and 365 nM. Butyrylcholinesterase had higher affinity for R-ethopropazine.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740955     DOI: 10.1016/j.biochi.2011.06.023

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  7 in total

1.  Characterization of butyrylcholinesterase in bovine serum.

Authors:  Alicia J Dafferner; Sofya Lushchekina; Patrick Masson; Gaoping Xiao; Lawrence M Schopfer; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2017-02-08       Impact factor: 5.192

2.  Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.

Authors:  Fang Wu; Lu Gaohua; Ping Zhao; Masoud Jamei; Shiew-Mei Huang; Edward D Bashaw; Sue-Chih Lee
Journal:  Pharm Res       Date:  2014-03-04       Impact factor: 4.200

3.  First chemoenzymatic stereodivergent synthesis of both enantiomers of promethazine and ethopropazine.

Authors:  Paweł Borowiecki; Daniel Paprocki; Maciej Dranka
Journal:  Beilstein J Org Chem       Date:  2014-12-18       Impact factor: 2.883

4.  Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study.

Authors:  Terrone L Rosenberry; Xavier Brazzolotto; Ian R Macdonald; Marielle Wandhammer; Marie Trovaslet-Leroy; Sultan Darvesh; Florian Nachon
Journal:  Molecules       Date:  2017-11-29       Impact factor: 4.411

5.  Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold.

Authors:  Anita Bosak; Alma Ramić; Tamara Šmidlehner; Tomica Hrenar; Ines Primožič; Zrinka Kovarik
Journal:  PLoS One       Date:  2018-10-05       Impact factor: 3.240

6.  Probing the peripheral site of human butyrylcholinesterase.

Authors:  Ian R Macdonald; Earl Martin; Terrone L Rosenberry; Sultan Darvesh
Journal:  Biochemistry       Date:  2012-08-27       Impact factor: 3.162

7.  Benzobicyclo[3.2.1]octene Derivatives as a New Class of Cholinesterase Inhibitors.

Authors:  Tena Čadež; Ana Grgičević; Ramiza Ahmetović; Danijela Barić; Nikolina Maček Hrvat; Zrinka Kovarik; Irena Škorić
Journal:  Molecules       Date:  2020-10-22       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.